semaglutide epilepsy A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025 Newer glucose‐lowering drugs reduce the

The SURMOUNT-1 data shows diminishing returns at higher doses: 5mg produced 15% weight loss, 10mg produced 19.5%, and 15mg produced 20.9%

Some of the common side effects noted in studies include: Headache Gastrointestinal upset (such as nausea) A temporary rise in estradiol levels While reports of mood changes or vision issues are less common than with clomiphene, they are still a possibility

The Fatty Liver Alliance gathered physician insights on metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), supplemented by a 2022 to 2023 US survey of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

This is the marker most influenced by selenium-dependent conversion

Here's what that means for your coverage

Extraocular motility and alignment testing was within normal limits